Examples of using Described in table in English and their translations into Polish
{-}
-
Medicine
-
Financial
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Official/political
-
Programming
-
Computer
Dose modifications due to peripheral neuropathy are described in Table 2.
Fixing rails at the grid(quantity described in table) are for mounting
The therapy may be initiated by titrating the dose as described in Table 1.
Tylvalosin is an allowed substance as described in Table 1 of the annex to Commission Regulation(EU) No 37/2010.
The risk control framework in the pooling system is described in Table 3.
Therapy may be initiated by titrating the dose as described in Table 1 or by administering 300 mg three times a day(TID) on Day 1.
discontinuation may be required as described in Table 3.
Baseline demographic characteristics are described in Table 6 below.
refer to the corresponding SmPC of these medicinal products as some combination regimens do not adhere to the ribavirin dose modification and/or discontinuation guidelines as described in Table 2.
The active substance in Loxicom is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
key secondary endpoints in these studies are described in Table 1.
The active substance in Inflacam is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) 37/2010.
recommended for severe or persistent neutropenia and thrombocytopenia as described in Table 1.
The active substance in Draxxin is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
The recommended dose of efavirenz in combination with a PI and/or NRTIs for patients between 3 and 17 years of age is described in Table 1.
The active substance in Melovem is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
flares in the two treatment arms are further described in Table 4 below.
A maximum of two consecutive dose reductions for each medicinal product, as described in Table 1, can be applied in case of toxicity.
weekly dose of darbepoetin alfa or epoetin at the time of substitution as described in Table 1.
Dosage adjustment is recommended in patients with compromised renal function as described in Table 2 and/ or those undergoing haemodialysis.
weekly dose of darbepoetin alfa or epoetin at the time of substitution as described in Table 1.
coupon structure of the debt instruments as described in Table 7 for eligible marketable fixed coupon
stomatitis, the Caelyx dose should be modified as described in Table 1 and 2 above respectively.
The active substance in Pirsue 5mg/ml intramammary solution for cattle is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
pigs is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
horses is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
pigs is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.
horses is an allowed substance as described in table 1 of the annex to Commission Regulation(EU) No 37/2010.